Differential methylation analysis was performed using the MethLAB R-based programme [4] using R (version 2.15.0). The program enables us to identify significantly differentially methylated CpGs from the corrected beta values. It utilises a t-statistic model, with linear regression and FDR correction. For the analysis, the beta values were converted to M values. M-value = log2 [Beta value/1-Beta value] The linear model with the factor of interest (tumour type -pilocytic, diffuse, control) was computed, with other varying factors; bead chip number (1-5), BRAF status (fusion, V600E mutation, WT), sample location (infratentorial/supratentorial), age group (fetal/HNSC, <3 years, >=3 years, >16 years) and sex (male, female) included in the model. A class covariance and FDR correction (Benjamini-Hochberg) were performed. Files entered into the program are the corrected β-values for each sample (Illumina probe ID and β-values excluding probes on the Chr X and Y), a phenotype file (includes sample group (pilocytic, diffuse, normal brain controls), bead chip, BRAF status, sample location, age and sex) and the 450K annotation file. Comparisons performed are shown below (statistically significant CpG sites had FDR-corrected p-value <0.05). The linear model is the linear relationship between dependent variable and independent variables (n). In this analysis the dependent variable is the β-value for each probe and the independent variables are the phenotypic factors such as tumour type. To identify tumour-specific changes the other independent variables are taken into account. For identification of key differentially methylated CpG sites it has been shown that the recommended sensitivity for differential analysis using the Illumina bead chip technology is a delta beta value >0.2 [1]. For our analysis, differentially methylated CpG sites of interest had a differential change of ≥0.3 with FDR-corrected p-value <0.05. Results of the comparisons are shown in Supplementary Table 3. MethLAB comparison analyses-1) Pilocytic astrocytoma (n=17) v diffuse astrocytoma (n=10) v controls (n=5) -Mutation analysis The independent variable was firstly BRAF fusion status (BRAF fusion, n=12; No BRAF fusion, n= 20) and then BRAF status (BRAF fusion and BRAF V600E
3 that were computed between the tumours and controls, MethLAB analysis was not able to be performed on the full dataset. Therefore differential changes of >0.3 between the averaged sample groups were firstly calculated. The independent variable was sample type (pilocytic or foetal cerebellum or adult cerebellum). Analysis identified 11,671 CpG sites unique to the 3 groups (FDR-corrected p-values <0.05). 4) Supratentorial pilocytic astrocytomas (n=6) v diffuse astrocytomas (n=10) v each normal cerebral cortex group (foetal n=1, adult n=2, glial component n=4, neuronal component n=4) Normal cerebral cortex controls for the adult cortex were taken from GSE41826 [3] . The independent variable was sample type (pilocytic, diffuse, foetal cortex, adult cortex, glial and neuronal components). The co-variables included are bead chip and sex. Analysis identified 63,065 CpG sites that were unique to each of the 3 groups (FDR-corrected p-values <0.05).
Ingenuity Pathway Analysis (IPA) for genes associated with 993 differentially methylated sites identified in the three-way comparison of the test tumour set IPA analysis shows significant biological and disease categories including functional annotation (p-value <0.05), for 537 genes sorted by p-value. Additional file 9: Table S8 CpG sites which are present or absent from the hypomethylation signature comparisons between the test tumour set, published normal brain controls and published tumour sets
The 311 CpG sites were compared to published normal controls and tumour sets, and the data represented as heatmaps in Supplementary Figures 13 -16 . Some of the CpG sites were not represented in the comparison datasets; therefore the lists of present CpG sites are shown. The 311 CpG sites are ordered from low to high methylation in the pilocytic astrocytomas. Normal brain controls (1_Cerebellum [Lambert et al, Acta Neuropathologica 126:291-301, 2013] ; Cerebral cortex [Guintivano et al, Epigenetics 8:290-302, 2013] ); paediatric low-grade astrocytomas (2_validation tumour set 2; 3_ [Lambert et al, Acta Neuropathologica 126:291-301, 2013] ); adult low-grade astrocytomas (4_TCGA); paediatric and adult high-grade astrocytomas (5_[Sturm et al, Cancer Cell 22:425-437, 2012] ), medulloblastomas (6_ [Schwalbe et al, Acta Neuropathologica 126:943-946, 2013] ; Ependymomas (7_GSE45353 [Mack et al, Nature 506:445-450, 2014] ) and foetal brain during development (8_GSE58885 [Spiers et al, Genome Research 25:338-352, 2015] ).
Additional file 10: Table S9
Comparison of pilocytic astrocytomas with diffuse astrocytomas in the test tumour set 315 CpG sites are shown where δβ ≥ 0.3 (Benjamini-Hochberg corrected p-value <0.05), assessed by MethLAB.
Illumina annotation is included. Rows highlighted in grey (42/315 CpG sites) were absent in the 993 differentially methylated CpG sites between tumours and normal brain control. Ordered by chromosomal location.
Additional file 11: Table S10
Ingenuity Pathway Analysis (IPA) for genes associated with 315 differentially methylated sites in the test pilocytic and diffuse astrocytomas 1_ The 185 genes that were directly associated with 217/315 CpG sites. Enhancers (grey) and CpG probes that are present within more than one gene (#) are highlighted. 2_ IPA analysis shows significant biological and disease categories which includes their functional annotations (p-value <0.05), sorted by p-value.
Additional file 12: Table S11

Normalised log2 expression values for the genes associated with the 315 CpG sites
The δβ values between the pilocytic and diffuse astrocytoma groups were obtained from the grouped averaged beta values. Genes with a differential gene expression ≥2 fold are highlighted in grey. Sorted alphabetically by gene symbol.
Comparison of methylation and expression for genes associated with 315 differentially methylated sites in pilocytic and diffuse astrocytomas
Correlation coefficients are shown for differentially methylated CpG sites that show a difference of ≥2-fold in expression of the associated gene. Expression probes were only assessed if they were located within the mRNA transcript. A) CpG sites located within the promoter of the gene. B) CpG sites located within the gene body, 3'UTR and intergenic regions. As the CpG is not within a promoter, correlation was also calculated for a CpG site within the promoter (where possible within the TSS200; brown panel). For each correlation p-values and Benjamini-Hochberg corrected p-values are shown. The table is ordered by FDR-corrected p-values (sites with a p-value <0.05 are shown in blue). Positive correlation is highlighted in yellow. Up-regulated genes in diffuse astrocytomas are highlighted in green. When the expression probe was located in an exon, the probe for the full transcript was used for the correlation (indicated by the asterisk).
Additional file 14: Table S13
Functions of genes which show a significant correlation between DNA methylation and gene expression.
The majority of genes were hypomethylated in pilocytic astrocytomas except the genes highlighted in bold, which were hypermethylated in the pilocytic astrocytomas.
Additional file 15: Table S14
Predicted transcription factor binding sites for the 315 differentially methylated signature in low-grade astrocytomas Table to show TRANSFAC predicted transcription factor binding sites within a 200bp region (100bp either side of the CpG site detected by the Illumina probe). Illumina annotation highlighted in grey and transcription factor binding predictions plus sequence highlighted in blue. List of the top predicted transcription factors and gene expression levels of the top predicted transcription factors for the low-grade astrocytomas are also shown.
Additional file 16: Table S15
Differential expression of AP-1 target genes in pilocytic astrocytomas compared to normal brain controls (6):235-242, 2011] and predicted AP-1 target genes identified in the 315 differentially methylated sites. 2_ Table showing AP-1 target genes that are differentially expressed in pilocytic astrocytomas compared to normal brain controls and diffuse astrocytomas. For each gene, methylation and expression status, plus the normalized log2 transformed expression values for each sample are included. The data is ordered by correlation with FOS expression (positive to negative correlation). The colour coordination shows which genes were taken from the 3 lists.
Additional file 17: Table S16
The differentially methylated CpG sites within de-regulated genes from the comparison between infratentorial pilocytic astrocytomas and normal cerebellum controls 1_ Features of 11, 671 probes that are significantly differentially methylated in infratentorial pilocytic astrocytomas compared to published foetal and adult normal cerebellum datasets (averaged beta values with a difference of δβ ≥ 0.3, Benjamini-Hochberg corrected p-value <0.05 [Lambert et al, Acta Neuropathologica 126:291-301, 2013] ). 2_ Normalized log2 transformed expression analysis identifies differentially expressed genes between infratentorial pilocytic astrocytomas (n=4) compared to normal cerebellum (n=2, foetal and adult cerebellum). Genes that show fold change >2 are highlighted. 3_ List of genes that have differential methylation (δβ ≥ 0.3) and differential gene expression (fold change >2).
Additional file 18: Table S17
Ingenuity Pathway Analysis (IPA) of genes associated with differentially methylated sites in infratentorial pilocytic astrocytomas and normal cerebellum IPA analysis of the top 20 significant biological and disease categories including their functional annotation (pvalue <0.05) identified for 161 genes that had ≤2 fold change in gene expression and δβ ≥ 0.3, sorted by pvalue.
Additional file 19: Table S18
Differentially methylated CpG sites identified between supratentorial pilocytic astrocytomas and cerebral cortex controls Additional file 20: Table S19 Differentially methylated CpG sites identified between diffuse astrocytomas and cerebral cortex controls 1_ MethLAB analysis identified 90,249 CpG sites that are significantly differentially methylated in supratentorial pilocytic astrocytomas, diffuse astrocytomas, glial component of the cerebral cortex, neuronal component of the cerebral cortex, adult cerebral cortex and foetal cerebral cortex (Benjamini-Hochberg corrected p-value <0.05). The adult cerebral cortex controls (including the glial and neuronal components) were taken from [Guintivano et al, Epigenetics 8:290-302, 2013] . The number of differentially methylated sites (averaged beta values with a difference of δβ ≥ 0.3, Benjamini-Hochberg corrected p-value <0.05) identified in tumour and all controls was 58 CpG sites for the diffuse astrocytomas. 2_ CpG sites hypermethylated and 3_ hypomethylated in diffuse astrocytomas compared to controls. 4_ Expression analysis for the genes that show differentially methylated CpG sites. Highlighted genes show ≤ 2 fold change in expression compared to controls.
Additional file 21: Table S20
Differentially methylated CpG sites in infratentorial pilocytic astrocytomas, supratentorial astrocytomas and diffuse astrocytomas 1_ MethLAB analysis identified 676 CpG sites that are significantly differentially methylated in infratentorial pilocytic, supratentorial pilocytic and diffuse astrocytomas (Benjamini-Hochberg corrected p-value <0.05). 2_
The 72 differentially methylated CpG sites in supratentorial and infratentorial pilocytic astrocytomas. 3_ The 393 differentially methylated CpG sites for infratentorial pilocytic astrocytomas and diffuse astrocytomas (averaged beta values with δβ ≥ 0.3, Benjamini-Hochberg corrected p-value <0.05). 4_ Genes that show differentially methylated CpG sites and expression between supratentorial and infratentorial pilocytic astrocytomas (genes with fold change > 2 highlighted in grey).
SUPPLEMENTARY FIGURES Supplementary Figure 1. Correlation between Illumina 450K BeadChip and pyrosequencing analysis of methylation of CpG sites within 5 genes for the test tumour set
Correlation coefficients were calculated for the matching 450K (beta values) and pyrosequencing (% methylation) values at selected CpG sites (gene names and Illumina probe identifiers shown). R-values range from 0-1 with strong correlation having values close to 1. Tumours and controls tested are: pilocytic astrocytomas (PA, n=11), diffuse astrocytomas (DA, n=9) and normal brain controls (AB, Adult brain; FFL, foetal frontal lobe; FB, foetal brain; FCB, foetal cerebellum, n=4). 
astrocytomas with methylation in an adult low-grade astrocytoma cohort and a high-grade glioma cohort
Heatmaps showing the hypomethylation signature in (a) Adult low-grade astrocytoma cohort (TCGA) and (b)
Adult and paediatric glioblastoma cohort (GSE36278, [10] ). Columns represent individual samples; rows 311
CpG probes ( Supplementary Table 18 ). Methylation beta values are represented in shades of yellow = 0 (unmethylated) to blue = 1 (methylated). Study test tumours are shown, pilocytic (n=17) and diffuse (n=10) astrocytomas left of the red line. ( Supplementary Table 8 ).
astrocytomas with methylation in a medulloblastoma and an ependymoma cohort
Heatmap showing the hypomethylation signature in (a) Medulloblastoma cohort (n=60, grouped according to their molecular status; [8] ) and (b) Ependymoma cohort (n=36); [6] . Columns represent individual samples; rows represent 450K CpG probes. Methylation beta values are represented in shades of yellow = 0 (unmethylated) to blue =1 (methylated). Study test tumours are shown, pilocytic (n=17) and diffuse (n=10) astrocytomas. As values were missing from the cohorts, 291/315 CpG sites for medulloblastoma and 295/315 CpG sites for ependymomas are shown ( Supplementary Table 8 ). Figure 13 . Differential methylation within the CCND1 gene and comparison with SNP status and levels of gene expression.
Supplementary
(a)
A 372bp region covering all of exon 4 and 224bp of intron 4 was Sanger-sequenced to identify the methylation status of the 11 CpG sites located within this region (a.i). Qualitative methylation status was assigned to each CpG site for 4 normal brain controls, 9 diffuse astrocytomas and 23 pilocytic astrocytomas 
